News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Highland Instruments, Inc. , Announces Institutional Review Board ("IRB") Approval to Initiate Clinical Evaluation of Non-Invasive Brain Stimulation Technologies In Patients With Parkinson's Disease


10/23/2012 9:05:46 AM

BOSTON--(BUSINESS WIRE)--Highland Instruments, Inc., (“Highland”) today announced IRB approval to initiate a clinical evaluation of Highland’s ElectroSonic Stimulation (“ESStim™”) technology for the treatment of Parkinson’s Disease (“PD”)1. The clinical evaluation “Effects of Non-Invasive Neurostimulation Methods on Motor Function in Parkinson’s Disease Patients” will be conducted at the Spaulding Rehabilitation (“Spaulding”) Hospital’s Laboratory of Neuromodulation (Boston). Felipe Fregni, MD, PhD, MPH, will be the Lead Clinical Investigator. Dr. Fregni is the Director of the Laboratory of Neuromodulation at Spaulding Rehabilitation Hospital and Associate Professor of Neurology at Harvard Medical School. Bill Edelman, Chairman of the Board for Highland, commented, “We are thrilled to have received IRB approval to initiate the clinical evaluation of ESStim in patients with Parkinson’s Disease. Dr. Fregni is a pioneer in the world of non-invasive brain stimulation, having conducted groundbreaking trials exploring neuromodulation treatments for chronic pain, Parkinson's disease, and stroke.”

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES